While primary care systematically offers conventional cardiovascular risk assessment, genetic tests for coronary heart disease (CHD) are increasingly commercially available to patients. It is unclear how individuals may respond to these new sources of risk information.
INTRODUCTION
Cardiovascular disease (CVD) is the top cause of death globally; 1 it causes a third of deaths worldwide 2 and is projected to remain the single leading cause of death. 3 To help identify individuals at increased risk of it, many clinicians use riskassessment tools, such as those using the Joint British Societies' (JBS2) and QRISK2 tools. 4, 5 The former is based on the Framingham algorithm to give a probability of developing a cardiovascular event within the next 10 years, and gives GPs a basis and rationale on which to prescribe medication to reduce overall CVD risk. [6] [7] [8] The JBS2 tool and a few other cardiovascular risk assessment tools take account of a family history of premature CHD as a proxy for genetic predisposition. 4, 5, 7, 9 Recent genome studies have identified genetic variants, such as the 9p21 gene, as strong independent risk factors for CHD. This information may have clinical utility in reclassifying CHD risk. [10] [11] [12] At the same time, predictive genetic tests are increasingly being offered commercially, directly to consumers over the counter. 13 The current limitations of this type of genetic testing are not always considered, with both participants and clinicians not fully understanding the test results. 14, 15 This may lead either to false reassurance or unnecessary increased stress or anxiety. 14 However, using genetic testing in primary care could be useful as a tool to encourage risk-reducing behaviour in those at risk of developing CVD. [16] [17] [18] Arguably, this may be more effective than conventional cardiovascular risk assessment alone, as genetic risk may seem more personal and salient than family history. 19 In this study, adults who had had a recent cardiovascular risk assessment in general practice were offered a genetic test for CHD to explore the acceptability and feasibility of the procedure and assessment. This article reports a qualitative exploration with participants on how they made sense of the additional information from genetic testing and their perceptions of whether this influenced their behaviour.
METHOD Design
This qualitative interview study formed part of a wider mixed-methods study to evaluate the feasibility and clinical utility of genetic testing as part of conventional cardiovascular risk assessment.
Participants
The consenting participants came from 12 practices in Nottinghamshire from both urban and rural settings and had had a conventional cardiovascular risk assessment within the last 18 months.
Background
While primary care systematically offers conventional cardiovascular risk assessment, genetic tests for coronary heart disease (CHD) are increasingly commercially available to patients. It is unclear how individuals may respond to these new sources of risk information.
Aim
To explore how patients who have had a recent conventional cardiovascular risk assessment, perceive additional information from genetic testing for CHD.
Design and setting
Qualitative interview study in 12 practices in Nottinghamshire from both urban and rural settings.
Method
Interviews were conducted with 29 adults, who consented to genetic testing after having had a conventional cardiovascular risk assessment.
Results
Individuals' principal motivation for genetic testing was their family history of CHD and a desire to convey the results to their children. After testing, however, there was limited recall of genetic test results and scepticism about the value of informing their children. Participants dealt with conflicting findings from the genetic test, family history, and conventional assessment by either focusing on genetic risk or environmental lifestyle factors. In some participants, genetic test results appeared to reinforce healthy behaviour but others were falsely reassured, despite having an 'aboveaverage' conventional cardiovascular risk score.
They were individuals who had, previously, received their conventional cardiovascular risk assessment and had chosen to have a genetic test, as well as agreeing to a followup interview. The interviews were carried out 4 months after patients received their risk status. On recruitment, the study pack included a family-history questionnaire enquiring about CHD in first-and seconddegree relatives.
The CHD genetic test (which is commercially available) involved collecting a saliva sample from the participant and sending it for analysis to University College London's cardiovascular genetic laboratory. It comprised a cardiovascular panel of nine risk alleles to produce a combined risk profile score.
Participants were sent a letter outlining the results of their conventional risk assessment, genetic test, and their overall cardiovascular risk. The letter presented both the conventional assessment and genetic test results in terms of average and above-average risk. In line with other risk-assessment tools, these were classified as follows:
• average risk; at or near population risk; and
• above-average; greater than population risk.
In the conventional cardiovascular risk assessment, average was <10% risk of developing CVD in the next 10 years and above average was ≥10% risk. 4, 5 To avoid the study interfering with participants' adherence to current CVD risk-assessment recommendations, 5 if the conventional cardiovascular risk assessment suggested above-average risk and the genetic test indicated that risk was average, participants were advised that they were still at above-average risk of developing CVD.
Interview schedule
Participants were asked about their:
• conventional risk assessment, which had been undertaken at the practice;
• experience of the genetic test; and
• interpretations and perceptions of the results of both assessments.
Their views on whether results had or had not influenced any change in their behaviours over the 4 months of the study were also explored.
Analytical approach
All interviews were transcribed verbatim. Interview data were managed using Atlas. ti (version 5). Thematic analysis was used, 20 and codes and themes developed iteratively as data were analysed. 21 Codes were both deductive (derived from the interview schedule) and inductive (data driven).
RESULTS
A total of 320 individuals who had had a conventional CVD risk assessment were offered genetic testing. Of those, 119 agreed to have the test and 30 consented to be interviewed; one potential participant was excluded from the interview because of psychosocial reasons. Table 1 outlines the participants' characteristics for both the main feasibility study and this qualitative study. Like the main study, most participants were males in their mid-50s to mid-60s, while in the qualitative study 41% had qualifications equivalent to, or greater than, A-levels. Of the 29 participants, seven had genetic test results that showed above-average risk, with four of these reporting a family history of CHD. The genetic test results of the remaining 22 participants showed they were at average risk; 13 of these had recalled a family history of CHD.
The age range of the 119 participants in the main feasibility study and the 29 interviewees was similar (median 59 years; interquartile range [IQR] 53-62 years). Proportionally, more males (72.4% versus 58.0%) and more individuals who were educated to undergraduate degree level (34.5% versus 18.5%) participated in the interviews.
In terms of being categorised differently in the conventional assessment and the genetic test, when compared with all the study participants, more from the qualitative study
How this fits in
Cardiovascular risk assessment using conventional risk factors is routine in primary care but 'direct-to-consumer' genetic testing for coronary heart disease (CHD) is now easily available, particularly online. This study indicates that uptake of genetic testing for CHD may be particularly attractive to patients with a family history of the condition. When encountering individuals who have had genetic testing, GPs need to explore the individual's understanding of the results in light of their family history and the previous conventional risk assessment to ensure adherence with risk-reducing behaviour.
had an above-average conventional CVD risk assessment score and an average genetic test score (72.4% versus 54.6%). Further, proportionally less interview participants were categorised as having an average risk score on both conventional CVD assessment and CHD genetic test (3.4% versus 26.1%).
Five main themes emerged:
• motivation to have genetic testing;
• recall and initial reaction to conventional risk assessment and genetic test results;
• reconciling conflicting information;
• responses to genetic test result; and
• future role of genetic testing.
Motivation to have genetic testing
Family history. The predominant motivation for participants accepting an offer of genetic testing was a family history that they wished to clarify further. For some, this related to a specific relationship -for example a parent or sibling with CHD -whereas, for others, it concerned relatives scattered across several generations. Anxiety about premature death due to family history was expressed by only a minority of participants, with some saying this subsided when they had passed the age of their relative's death:
'Well my father died aged 49 with coronary heart, you know, coronary thrombosis, so I just assumed there might be something in the family, something genetic and it was very difficult when I reached that age … I was thinking, you know, "is this my time up?" But obviously it wasn't thankfully.' (Participant 12, male, 62 years, aboveaverage CVD assessment result, average genetic test result, CHD family history, educated to degree level) '… and my grandfather on his side was, er, suffered with heart problems … which really made me think if I don't look after what is going off, I need to be sort of sure of what is happening and, if it is going to be genetic, then it's going to come my way.' (Participant 24, male, 63 years, aboveaverage CVD assessment result, average genetic test result, CHD family history, educated to degree level)
Benefit to children. Responders also reported being tested to be able to discuss the outcome with their children. They felt the results would be useful for their offspring, who could make informed decisions if it was felt they should consider ways to reduce their own risk of developing CHD in the future: 'The reason I was interested ... was because my dad died in 1989 ... I believe it was the cardiovascular but I don't know. He was 62. It's young isn't it? So, obviously, I have got children of my own and so I need to make sure that it's not something that I am likely to pass on or have already passed on ... So all I am interested in, in reality, is protecting my kids and myself. And I think through this genetic thing we should be able to do it hopefully.' (Participant 4, male, 57 years, above-average CVD assessment result, average genetic test result, CHD family history, educated to vocational level) However, at interview, very few participants had made their children aware of the genetic test. Although children were It was uncommon for participants to describe experiencing anxiety after receiving their genetic test result but, where this was expressed, it was seen as a motivator to reduce risk:
'Well, it scares me ... Erm, well, obviously, I want to do everything I possibly can to avoid, erm, to avoid getting any heart disease.' (Participant 16, female, 42 years, average CVD risk assessment result, above-average genetic test result, CHD family history, 'other' education)
Future role of genetic testing
Testing using a saliva sample was considered to be acceptable to participants; none expressed concerns about the procedure. Some suggested this should be offered to the general public: 'Er, no I think it ought to be available to everybody if they want to do it. Some people might think "I would rather not know".' (Participant 3, male, 62 years, above-average CVD risk assessment result, average genetic test result, CHD family history, educated to A level) An older participant made the point that a genetic test was more appropriate for a younger age group, in whom preventative activities were more likely to lead to potential health benefits:
'I think 25 ... At least it would point to them and, er, give them plenty of time to adjust to the lifestyle -if they want to, of course ...' (Participant 3, male, 62 years, above-average CVD risk assessment result, average genetic test result, CHD family history, educated to A-level standard)
Others expressed concerns about relying on genetic test results and said that more research was required to identify further predictive genes for CHD: 'There will be a load of other genes that you don't know about yet … I haven't interpreted to mean that I haven't got any genes that are involved that might increase my cardiovascular risk you know. I don't take it to mean that it's all environmental … I think there are probably other genes that will affect one's cholesterol, metabolism, and one's blood pressure, or whatever, that you perhaps haven't mapped yet.' (Participant 23, female, 53 years, above-average CVD risk assessment result, average genetic test result, CHD family history, 'other' education)
A participant who had experience with screening for another medical condition highlighted concerns that genetic testing may lead to insurance liabilities and break confidentiality:
'The only reason I took part in this genetic test was because it was guaranteed to be confidential and not passed on to any other party.' (Participant 20, male, 57 years, average CVD risk assessment result, above-average genetic test result, reports CHD family history, educated to GCSE/Olevel/CSE level)
DISCUSSION

Summary
The principal driver for undertaking genetic testing was a perceived familial risk of developing CHD, with participants often motivated by a desire to convey the results to their children. After testing, however, some participants demonstrated limited recall of their results and scepticism about the value of passing the information to their offspring.
Participants had to deal with the fact that sometimes results from the genetic test, family history, and conventional cardiovascular risk assessment conflicted with each other. For some participants, the ways of dealing with this included either focusing on the genetic risk or the environmental lifestyle risk factors; others were sceptical about the value of the genetic test results.
In some participants the genetic test results appeared to reinforce healthy behaviour; others were falsely reassured by having an average score despite their conventional cardiovascular risk score being above average.
Participants found the testing procedure acceptable, and suggestions were made that genetic testing could lead to potential benefits for younger individuals by encouraging them to adopt risk-reducing behaviour.
Strengths and limitations
To the study's knowledge, this is the first study to explore the impact of genetic testing in individuals who have been offered a CVD risk assessment in primary care. Previous studies have only explored the reactions of participants to hypothetical genetic testing scenarios. 22 This qualitative study explored the views of a self-selected sample of people who consented to genetic testing and followup interview. Although the participants were recruited from all of those who were undergoing cardiovascular risk assessment in a range of British general practices, there was limited participation by younger individuals, those from minority ethnic groups, and those from areas of deprivation.
Compared with all participants in the main feasibility study, proportionally more interviewees had an above-average conventional assessment result and an average genetic test result. However, the views of participants with a wide range of conventional and genetic cardiovascular risk profiles were captured.
Participants struggled to recall their genetic test results and had to be reminded of these during the interview; however, they were still able to give reasonable insight into their reaction to the results. This suggests that patients should be provided with more detailed information in the results letter.
The study had limited opportunity to examine any reported impact of genetic testing on behavioural change as many participants said they had already adopted healthy lifestyles prior to this study being undertaken.
Comparison with existing literature
To the study's knowledge this is the first study to evaluate patients' perspectives of genetic testing in the context of cardiovascular risk assessment in primary care. The majority of previous studies have explored the role of genetic testing in assessing the risk of specific monogenic diseases such as Huntington's disease, familial hypercholesterolaemia, and, more generally, in genetic risk assessments for cancer. [23] [24] [25] [26] [27] Participants' opinions have also been ascertained in hypothetical scenarios. 28, 29 In this study, a perceived familial risk of CHD was a major driver for requesting genetic testing. This parallels the findings in studies of heart disease and breast cancer in secondary care. [30] [31] Similar to this study, Lerman et al noted that most participants were motivated to know whether this predisposition would affect others in the family. 31 However, the study also found that, after testing, some participants expressed scepticism about the value of passing on this information to their children. Further, participants with average genetic risk results found it difficult to reconcile these results with knowing that they had a family history of CHD. This is similar to the reported impact of a negative genetic test result for familial hypercholesterolaemia, which led to participants feeling 'in limbo' about their raised blood cholesterol. 23 In this study, fatalism was reported in one individual only. This limited discussion is similar to studies communicating genetic test results to participants with a family history of familial hypercholesterolaemia. 23, 24 Previous studies exploring the value of genetic testing in modifying risk-reducing behaviour have been disappointing. For those who underwent genetic testing for diabetes, myocardial infarction, and cancer, there has been little or no effect on longterm abstinence of smoking or short-term changes in diet and exercise. 22, 28, 32 There are concerns that negative genetic test results for CVD may lead to false reassurance, while positive results may induce unnecessary anxiety in others. 33 In this study, the false reassurance was identified but not related to above-average results.
Implications for practice
GPs are currently struggling to interpret conventional cardiovascular risk assessment scores and communicate the results to patients. 34, 35 Even if there was adequate analytical and clinical validity of these CHD genetic tests, 36 until the fundamental issues of clinicians' confidence in interpreting and communicating cardiovascular risk are resolved, incorporating genetic test results may be premature. 35 However, GPs are exposed to genetic testing by patients presenting to discuss the results of commercially available (over-the-counter) CHD genetic tests.
14 GPs will usually be the first point of contact and will need to explore the patient's understanding of potentially conflicting results from genetic testing and conventional cardiovascular risk assessments. However, many clinicians indicate a lack of awareness on the subject and feel unprepared to manage such patients. 37 Further, in the future, genetic testing may be incorporated into primary care as a way of personalising the conventional cardiovascular risk assessment. In this instance, consideration will need to be given to the confidentiality of this information. 15, 33, 38 Although genetic testing in isolation may have limited utility, a high genetic risk score, in combination with a positive family history and an above-average conventional CVD risk assessment, may indicate a subgroup of the general population at particularly high risk of developing CVD and should be targeted for intensive lifestyle advice and lipid-lowering therapy.
Prior to implementing further research on the clinical utility of CHD genetic testing, further exploration of the best way to present the results to participants should be undertaken, as participants in this study did not understand the 'average' and 'above-average' classifications.
Any follow-up study might usefully involve a younger population and, as such, not be anchored to only those undergoing cardiovascular risk assessment (who are, in general, aged >40 years). To improve generalisability, future studies should actively recruit participants from various backgrounds including minority ethnic communities and groups who are underserved. It would also be beneficial to follow the participants over a longer period of time to see whether intentions to change behaviours did lead to actual behavioural changes.
CONCLUSION
These results add to the existing knowledge about patients' perceptions and understanding of their CHD risk, as identified by genetic testing. Participants had no concerns about testing procedures but, as they may make different judgements about their perceived risk of developing CVD in the light of their genetic risk result, health professionals need to explore patients' understanding of the conventional cardiovascular risk assessment, their perceived family history, commercially available genetic tests, and the impact of any discrepancy between the test and risk assessment on risk-reducing behaviour. 
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